Chemocentryx, Inc.

Amgen Inc.

Theravance, Inc.

Theravance Biopharma R&d Ip, LLC

Christopher W Lange

Penglie Zhang

Sreenivas Punna

Ju Yang

Venkat Reddy Mali

Viengkham Malathong

Rebecca M Lui

Yibin Zeng

Jay Patrick Powers

Pingchen Fan

Rajinder Paul Singh

Manmohan Reddy Leleti

Junfa Fan

Jeffrey P McMahon

Hiroko Tanaka

Yandong Li

Darren J McMurtrie

Antoni Krasinski

Trevor T Charvat

YongQi Mu

Craig Husfeld

Yuhua Ji

Rick Andrew Lee

Dean R Dragoli

Daniel J Dairaghi

Howard S Roth

Matthew J Walters

Joanne Tan

Ryan J Scamp

Jaroslaw Kalisiak

Yu Wang

Solomon Ungashe

Darren J McMURTRIE

Hiufung Chu

Timothy J Sullivan

Yu-Hua Ji

Jeffrey P McMAHON

Daniel R Marshall

Aubrie Harland

Jeffrey Mcmahon

Jarek Kalisiak

Jeffrey P MacMahon

Jeffrey P Mcmahon

Yongqi Mu

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Azetidinyl-acetamides as CXCR7 inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, A, Z, Xand n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors

Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Substituted anilines as CCR(4) antagonists

CXCR7 antagonists

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):

Immunomodulator compounds

6-5 fused rings as C5a inhibitors

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Indane-amines as PD-L1 antagonists

Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R, R, R, R, R, R, R, R, R, R, R, R, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, R, R, R, R, Rand the subscript n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds for treatment of PD-L1 diseases

Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors

5-5 fused rings as C5a inhibitors

Growing community of inventors

El Cerrito, CA, United States of America

Christopher W Lange